Published: 7 August 2020
Author(s): Marianna Adamo, Salvatore Curello, Marco Metra
Issue: January 2021
Section: Letter to the Editor

Trans-catheter aortic valve implantation (TAVI) is by now considered the treatment of choice in patients with severe and symptomatic aortic stenosis deemed at prohibitive or high surgical risk. However, recent evidence has led to broaden TAVI indication to intermediate and low-risk patients [1]. This implies better technologies and minimizing acute complications such as pacemaker implantation, vascular injury, renal failure and radiological exposure [1,2].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.